HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
UNLABELLED: NAFLD is the most common liver disease worldwide but it is the potential evolution to NASH and eventually to hepatocellular carcinoma (HCC), even in the absence of cirrhosis, that makes NAFLD of such clinical importance. AIM: we aimed to create a mouse model reproducing the pathological spectrum of NAFLD and to investigate the role of possible co-factors in promoting HCC. METHODS: mice were treated with a choline-deficient L-amino-acid-defined-diet (CDAA) or its control (CSAA diet) and subjected to a low-dose i.p. injection of CCl4 or vehicle. Insulin resistance was measured by the euglycemic-hyperinsulinemic clamp method. Steatosis, fibrosis and HCC were evaluated by histological and molecular analysis. RESULTS: CDAA-treated mice showed peripheral insulin resistance at 1 month. At 1-3 months, extensive steatosis and fibrosis were observed in CDAA and CDAA+CCl4 groups. At 6 months, equal increase in steatosis and fibrosis was observed between the two groups, together with the appearance of tumor. At 9 months of treatment, the 100% of CDAA+CCl4 treated mice revealed tumor versus 40% of CDAA mice. Insulin-like Growth Factor-2 (IGF-2) and Osteopontin (SPP-1) were increased in CDAA mice versus CSAA. Furthermore, Immunostaining for p-AKT, p-c-Myc and Glypican-3 revealed increased positivity in the tumors. CONCLUSIONS: the CDAA model promotes the development of HCC from NAFLD-NASH in the presence of insulin resistance but in the absence of cirrhosis. Since this condition is increasingly recognized in humans, our study provides a model that may help understanding mechanisms of carcinogenesis in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Bacterial translocation can be defined as the passage of bacteria, or bacterial products such as LPS, into the portal circulation and happens when the complex regulation of the mechanisms of the gut barrier is lost [276], which has been linked with the occurrence of NAFLD, NASH, hepatic fibrosis, and HCC in several rodent models [227,228,277].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [277]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“The severity was assessed by using the NAS scoring system [13].”
MethodManagement of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 1×
“Most of these ‘‘cryptogenic’’ HCC might be attributed to Non-Alcoholic Fatty Liver Disease (NAFLD) and the concomitant metabolic syndrome [2,3], nevertheless it is not yet clear what predisposes to the progression of the disease [4].”
BackgroundInflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Hepatocellular carcinoma pathogenesis: from genes to environment
Farazi, P. A., & DePinho, R. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1934 · Cited by 1,979 · cited 1×
“Indeed, HCC almost always develops on a background of chronic liver injury including chronic hepatitis and cirrhosis, conditions referred as preneoplastic stages [39].”
BackgroundMolecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 5×
“To investigate if CDAA was worsening also hepatic insulin resistance, we have measured the expression of liver enzymes associated with glucose production (G6Pase), gluconeogenesis (PEPCK) and de-novo lipogenesis as SREBP-1c and ChREBP [16,35].”
BackgroundInfluentialFausto, N., Campbell, J. S., & Riehle, K. J. (2006) · Hepatology · doi:10.1002/hep.20969 · Cited by 1,378
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Cited by
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“Accelerated by insulin resistance accumulating metabolites of saturated fatty acids cause lipotoxicity that damages hepatocytes and results in oxidative stress [214, 215].”
BackgroundNonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
“Also, mice fed a CDAA diet develop peripheral IR after 1 month of treatment, and a progressive increase in body weight (102).”
BackgroundTsuchida, T., Lee, Y. A., Fujiwara, N., Ybanez, M., Allen, B., Martins, S., Fiel, M. I., Goossens, N., Chou, H.-I., Hoshida, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.011 · Cited by 583
The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis
Saponaro, C., Gaggini, M., Carli, F., & Gastaldelli, A. (2015) · Nutrients · doi:10.3390/nu7115475 · Cited by 529
“Adipose tissue insulin resistance is likely to play a significant role since it is related to increased liver damage [124,131].”
BackgroundSelf-citationPierantonelli, I., & Svegliati-Baroni, G. (2019) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 460
Self-citationAnimal Models of Nonalcoholic Fatty Liver Disease—A Starter’s Guide
Van Herck, M., Vonghia, L., & Francque, S. (2017) · Nutrients · doi:10.3390/nu9101072 · Cited by 392
“However, the mean body weight was significantly lower in the HFD + CCl4 group compared to the HFD group and did not differ from the mean body weight of the control group.”
BackgroundInfluentialAdaptive immunity: an emerging player in the progression of NAFLD
Sutti, S., & Albano, E. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0210-2 · Cited by 374
Animal models of non‐alcoholic fatty liver disease: current perspectives and recent advances
Lau, J. K. C., Zhang, X., & Yu, J. (2017) · The Journal of Pathology · doi:10.1002/path.4829 · Cited by 373
“HCC developed after 9 months of feeding [62].”
BackgroundExperimental models of liver fibrosis
Crespo Yanguas, S., Cogliati, B., Willebrords, J., Maes, M., Colle, I., van den Bossche, B., de Oliveira, C. P. M. S., Andraus, W., Alves, V. A., Leclercq, I., et al. (2016) · Archives of Toxicology · doi:10.1007/s00204-015-1543-4 · Cited by 350
“Mimics the human main characteristics, namely obesity and peripheral insulin resistance Development of HCC can hinder the study of liver fibrosis De Minicis et al. (2014), Denda et al. (2002), Nakae et al. (1992) Common bile duct ligation”
Haldar, D., Kern, B., Hodson, J., Armstrong, M. J., Adam, R., Berlakovich, G., Fritz, J., Feurstein, B., Popp, W., Karam, V., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.011 · Cited by 313
Insulin-Like Growth Factor (IGF) System in Liver Diseases
Adamek, A., & Kasprzak, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051308 · Cited by 284
“According to the results of this research, CDAA model promoted the development of HCC from NAFLD/NASH in the presence of insulin resistance, but in the absence of cirrhosis [43].”
BackgroundResultHepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies
Alqahtani, A., Khan, Z., Alloghbi, A., S. Said Ahmed, T., Ashraf, M., & M. Hammouda, D. (2019) · Medicina · doi:10.3390/medicina55090526 · Cited by 265
“While the mechanism of NASH-related HCC is not fully understood, but the emerging evidence, suggesting the role of hyperinsulinemia secondary to insulin resistance, leads to increased expression of the insulin-like growth factor-1 (IGF-1), which triggers signaling cascade via insulin receptor substrate-1 (IRS-1) and e…”
BackgroundLipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease
Svegliati-Baroni, G., Pierantonelli, I., Torquato, P., Marinelli, R., Ferreri, C., Chatgilialoglu, C., Bartolini, D., & Galli, F. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.05.029 · Cited by 249
Self-citationNonalcoholic fatty liver disease and hepatocellular carcinoma
Zoller, H., & Tilg, H. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.010 · Cited by 174
Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research
Willebrords, J., Pereira, I. V. A., Maes, M., Crespo Yanguas, S., Colle, I., Van Den Bossche, B., Da Silva, T. C., de Oliveira, C. P. M. S., Andraus, W., Alves, V. A., et al. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.05.002 · Cited by 171
“Compensating the lack of weight gain and IR can be done by feeding rodents a choline-deficient L-amino acid diet, which also causes NAFLD [140].”
Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research
Flessa, C., Ansari, N. N., Kyrou, I., Leca, B. M., Lianou, M., Chatzigeorgiou, A., Kaltsas, G., Kassi, E. N., & Randeva, H. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415791 · Cited by 154
Kawaguchi, T., Charlton, M., Kawaguchi, A., Yamamura, S., Nakano, D., Tsutsumi, T., Zafer, M., & Torimura, T. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1723751 · Cited by 122
Rodent Models of Nonalcoholic Fatty Liver Disease
Zhong, F., Zhou, X., Xu, J., & Gao, L. (2019) · Digestion · doi:10.1159/000501851 · Cited by 136
Lysyl Oxidase‐Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis
Tan, H., Wang, N., Zhang, C., Chan, Y.-T., Yuen, M., & Feng, Y. (2020) · Hepatology · doi:10.1002/hep.31600 · Cited by 126
Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
Kutlu, Ö., Kaleli, H. N., & Ozer, E. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/8543763 · Cited by 116
“Binding of insulin or IGF-1 to their respective receptors, namely, insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R), triggers signaling cascade via insulin receptor substrate-1 (IRS-1) that results in activation of its downstream PI3K and MAPK pathways.”
BackgroundIkawa‐Yoshida, A., Matsuo, S., Kato, A., Ohmori, Y., Higashida, A., Kaneko, E., & Matsumoto, M. (2017) · International Journal of Experimental Pathology · doi:10.1111/iep.12240 · Cited by 98
“NAFLD–NASH–HCC mouse models involving administration of xenobiotic compounds show rapid progression of NASH to HCC, and the HCC incidence is relatively high in each (Fujii et al. 2013; De Minicis et al. 2014).”
BackgroundMorello, E., Sutti, S., Foglia, B., Novo, E., Cannito, S., Bocca, C., Rajsky, M., Bruzzì, S., Abate, M. L., Rosso, C., et al. (2018) · Hepatology · doi:10.1002/hep.29754 · Cited by 93
“Eightweek-old male hHIF-2a mice and related control sibling littermates not carrying the HIF-2a deletion were fed either a methionine/choline deficient (MCD) diet for 4 or 8 weeks or a choline-deficient L-amino acid–defined (CDAA) diet (Laboratorio Dottori Piccioni, Gessate, Italy) for 12 and 24 weeks.((26,27)) Contro…”
MethodWei, G., An, P., Vaid, K. A., Nasser, I., Huang, P., Tan, L., Zhao, S., Schuppan, D., & Popov, Y. V. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00041.2019 · Cited by 84
“One weakness of the HF-CDAA model must also be noted, specifically that the mice do not develop obesity and only mild insulin resistance (7).”
Pierantonelli, I., Rychlicki, C., Agostinelli, L., Giordano, D. M., Gaggini, M., Fraumene, C., Saponaro, C., Manghina, V., Sartini, L., Mingarelli, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11744-6 · Cited by 82
Self-citationPοlyzos, S. A., Chrysavgis, L., Vachliotis, I. D., Chartampilas, E., & Cholongitas, Ε. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.04.010 · Cited by 99
Chrysavgis, L., Giannakodimos, I., Diamantopoulou, P., & Cholongitas, Ε. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i3.310 · Cited by 93
Ngo, M.-H. T., Jeng, H.-Y., Kuo, Y., Nanda, J. D., Brahmadhi, A., Ling, T., Chang, T., & Huang, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041931 · Cited by 87
Pettinelli, P., Arendt, B. M., Teterina, A. A., McGilvray, I. D., Comelli, E. M., Fung, S. K., Fischer, S. E., & Allard, J. P. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205747 · Cited by 76
Chen, K., Ma, J., Jia, X., Ai, W., Ma, Z., & Pan, Q. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.11.005 · Cited by 75
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Self-citationPizarro, M., Solís, N., Quintero, P., Barrera, F., Cabrera, D., Rojas‐de Santiago, P., Arab, J. P., Padilla, O., Roa, J. C., Moshage, H., et al. (2015) · Liver International · doi:10.1111/liv.12794 · Cited by 66
“However, a detailed analysis of the effects of eplerenone on these pathways and on derangements of both carbohydrate and lipid metabolism in the CDAA model (18, 40) will be focus of future studies.”
BackgroundGrgurević, I., Božin, T., Mikuš, M., Kukla, M., & O’Beirne, J. P. (2021) · Cancers · doi:10.3390/cancers13225844 · Cited by 61
Achiwa, K., Ishigami, M., Ishizu, Y., Kuzuya, T., Honda, T., Hayashi, K., Hirooka, Y., Katano, Y., & Goto, H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.12.012 · Cited by 54
Romualdo, G. R., Leroy, K., Costa, C. J. S., Bacil, G. P., Vanderborght, B., da Silva, T. C., Barbisan, L. F., Andraus, W., Devisscher, L., Câmara, N. O. S., et al. (2021) · Cancers · doi:10.3390/cancers13215583 · Cited by 58
Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play
Charrez, B., Qiao, L., & Hebbard, L. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i8.2494 · Cited by 50
Guarino, M., Kumar, P., Felser, A., Terracciano, L., Guixé‐Muntet, S., Humar, B., Foti, M., Nuoffer, J., St–Pierre, M. V., & Dufour, J. (2020) · Cancers · doi:10.3390/cancers12061407 · Cited by 51
Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma
Raza, S., Rajak, S., Anjum, B., & Sinha, R. A. (2019) · Hepatoma Research · doi:10.20517/2394-5079.2019.014 · Cited by 54
“pathways, which are crucial in the pathogenesis of HCC since they induce cell proliferation and inhibit apoptosis([109]).”
BackgroundRoles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis
Chen, Y., & Tian, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01500 · Cited by 42
Hassan, N. F., Nada, S. A., Hassan, A. M., El‐Ansary, M. R., Al‐Shorbagy, M. Y., & Abdelsalam, R. M. (2019) · Inflammation · doi:10.1007/s10753-019-00967-6 · Cited by 48
Sircana, A., Paschetta, E., Saba, F., Molinaro, F., & Musso, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071745 · Cited by 48
Kessler, S. M., Laggai, S., Van Wonterg, E., Gemperlein, K., Müller, R., Haybaeck, J., Vandenbroucke, R. E., Ogris, M., Libert, C., & Kiemer, A. K. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00147 · Cited by 44
“Interestingly, genetic variants of the IGF2 gene were correlated to obesity, obesity-associated hypertension, and intramuscular fat (Faienza et al., 2010; Aslan et al., 2012; Deodati et al., 2013).”
BackgroundRadhakrishnan, S., Ke, J., & Pellizzon, M. (2020) · Current Developments in Nutrition · doi:10.1093/cdn/nzaa078 · Cited by 46
“Researchers also combine HFD feeding with chemicals such as streptozotocin or carbon tetrachloride (CCl4) to induce NASH in rat models (24, 55, 56).”
BackgroundMethodInfluentialArvanitakis, K., Koufakis, T., Kotsa, K., & Germanidis, G. S. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106261 · Cited by 39
Shao, G., Liu, Y., Lu, L., Zhang, G., Zhou, W., Wu, T., Wang, L., Xu, H., & Ji, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944088 · Cited by 39
Molecular mechanisms of hepatic fibrosis in chronic liver diseases
Rosso, C., Caviglia, G. P., Younes, R., Ribaldone, D. G., Fagoonee, S., Pellicano, R., & Bugianesi, E. (2020) · Minerva Biotecnologica · doi:10.23736/s1120-4826.20.02619-1 · Cited by 35
Long noncoding RNA H19 – a new player in the pathogenesis of liver diseases
Yang, Z., Zhang, T., Han, S., Kusumanchi, P., Huda, N., Jiang, Y., & Liangpunsakul, S. (2020) · Translational research · doi:10.1016/j.trsl.2020.11.010 · Cited by 34
Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
Tovo, C. V., de Mattos, Â. Z., Coral, G. P., SARTORI, G. D. P., Nogueira, L. V., Both, G. T., Villela‐Nogueira, C. A., & de Mattos, Â. A. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i2.343 · Cited by 36
Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges
Cigliano, A., Liao, W., Deiana, G. A., Rizzo, D., Chen, X., & Calvisi, D. F. (2024) · Biomedicines · doi:10.3390/biomedicines12071624 · Cited by 41
“The chronic administration of CCl4 and a choline-deficient L-amino-acid-defined diet (CD) for up to 9 months induce NASH with fibrosis and HCC [79].”
BackgroundNAFLD-Related HCC: Focus on the Latest Relevant Preclinical Models
Fang, J., Celton‐Morizur, S., & Desdouets, C. (2023) · Cancers · doi:10.3390/cancers15143723 · Cited by 27
“, Afp and Gpc3) is observed, and HCC develops after 36 weeks [87,88].”
BackgroundYang, J., He, J., Feng, Y., & Xiang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166440 · Cited by 29
Rodent models of fatty liver diseases
Bertola, A. (2018) · Liver Research · doi:10.1016/j.livres.2018.03.001 · Cited by 27
Tølbøl, K. S., Stierstorfer, B., Rippmann, J. F., Veidal, S. S., Rigbolt, K. T. G., Schönberger, T., Gillum, M. P., Hansen, H. H., Vrang, N., Jelsing, J., et al. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5395-7 · Cited by 24
Hepatocellular carcinoma in patients without cirrhosis
Sato‐Espinoza, K., Valdivia-Herrera, M., Chotiprasidhi, P., & Ferrer, J. D. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i23.107100 · Cited by 32
“IR upregulates insulin-like growth factor 1 (IGF-1), activating phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways, which promote cell proliferation and inhibit apoptosis[49].”
Foglia, B., Sutti, S., Cannito, S., Rosso, C., Maggiora, M., Autelli, R., Novo, E., Bocca, C., Villano, G., Ramavath, N. N., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.10.002 · Cited by 27
“Indeed, steatohepatitis not only promotes carcinogen-induced HCCs,(42) but also leads to their spontaneous development in mice fed a NASH-inducing choline-deficient diet.(43,44) Moreover, the lack of hepatocyte HIF-2a can reduce both the inflammatory response, as confirmed in this study in HCCs from hHIF-2a mice (Figu…”
BackgroundObesity‐Induced Upregulation of ZBTB7A Promotes Lipid Accumulation through SREBP1
Zhou, J., Ren, Y., Xu, Q., Song, Y., Zhou, F., Chen, M., Liu, J., Chen, L., & Pan, J. (2020) · BioMed Research International · doi:10.1155/2020/4087928 · Cited by 22
Progress in the Study of Animal Models of Metabolic Dysfunction-Associated Steatotic Liver Disease
Fu, Y., Hua, Y.-X., Alam, N., & Liu, E. (2024) · Nutrients · doi:10.3390/nu16183120 · Cited by 23
“Therefore, these models are primarily suited for liver-specific research [76,81].”
BackgroundCheraghpour, M., Hatami, B., & Singal, A. G. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.09.041 · Cited by 21
Kurhe, Y., Caputo, M., Cansby, E., Xia, Y., Kumari, S., Anand, S. K., Howell, B. W., Marschall, H., & Mahlapuu, M. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.09.018 · Cited by 20
“2 mL/g of body weight) of CCl4 (289116; Sigma-Aldrich) diluted (1:4 ratio) with corn oil (C8267; Sigma-Aldrich).(22) At age 36 weeks (for the DEN model) and 43 weeks (for the CDAA diet model), mice were killed after withholding”
MethodSouid, A., Giambastiani, L., Castagna, A., Santin, M., Vivarelli, F., Canistro, D., Morosini, C., Paolini, M., Franchi, P., Lucarini, M., et al. (2024) · Antioxidants · doi:10.3390/antiox13050596 · Cited by 18
Okishio, S., Yamaguchi, K., Ishiba, H., Tochiki, N., Yano, K., Takahashi, A., Kataoka, S., Okuda, K., Seko, Y., Liu, Y., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75805-z · Cited by 22
Plant-based foods and hepatocellular carcinoma: A review on mechanistic understanding
Saeed, R. A., Maqsood, M., Saeed, R. A., Muzammil, H. S., Khan, M. I., Asghar, L., Nisa, S. U., Rabail, R., & Aadil, R. M. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2095974 · Cited by 18
“…with overexpression of insulin-like growth factor-1 (IGF-1), Which in turn activates PI3K and MAPK pathways since both pathways play a key role in dysplastic hepatic cell development through apoptosis inhibition and enhanced cellular proliferation (De Minicis et al. 2014, Janku et al. 2014).”
BackgroundRecent Advances in Practical Methods for Liver Cell Biology: A Short Overview
Torres, S., Abdullah, Z., Brol, M. J., Hellerbrand, C., Fernández, M., Fiorotto, R., Klein, S., Königshofer, P., Liedtke, C., Lotersztajn, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062027 · Cited by 20
“In order to study the mechanisms produced in NASH pathology and the potential therapeutic targets, the models most commonly used are as follows [42]: dietary models, such as HFD, high-fructose diet [43], cholesterol and cholate diet [37], MCD diet [95] and choline-deficient l-amino acid-defined (CDAA) diet [96]; genet…”
MethodShimizu, Y., Tamura, T., Kemmochi, A., Owada, Y., Ozawa, Y., Hisakura, K., Matsuzaka, T., Shimano, H., Nakano, N., Sakashita, S., et al. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15239 · Cited by 16
Translational Aspects of Diet and Non-Alcoholic Fatty Liver Disease
Goossens, N., & Jornayvaz, F. R. (2017) · Nutrients · doi:10.3390/nu9101077 · Cited by 14
“In addition, 40% of mice developed HCCs (100% of animals in a combined intraperitoneal CCl4-CDAA arm) at nine months of diet [40].”
BackgroundAnimal Models of Non-alcoholic Fatty Liver Diseases and Its Associated Liver Cancer
Lau, J. K. C., Zhang, X., & Yu, J. Q. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_11 · Cited by 18
Mouse models of nonalcoholic steatohepatitis and their application to new drug development
Phung, H. H., & Lee, C. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01410-5 · Cited by 13
Košuta, I., Mrzljak, A., Kolarić, B., & Lovrenčić, M. V. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020560 · Cited by 13
“Furthermore, IR was associated with the development and recurrence of hepatocellular carcinoma (HCC) in patients with chronic HCV infection, regardless of the presence of diabetes [16,17].”
BackgroundKalra, S., Bhattacharya, S., & Rawal, P. (2021) · Medical Sciences · doi:10.3390/medsci9020039 · Cited by 14
Povero, D., Lazić, M., McBride, C., Ambrus-Aikelin, G., Stansfield, R. K., Johnson, C. D., Santini, A. M., Pranadinata, R. F., McGeough, M. D., Stafford, J. A., et al. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001639 · Cited by 13
“…effect of JT001 treatment on hepatic steatosis, inflammation, and fibrosis was evaluated in a second murine NASH model, the choline-deficient L-amino acid-defined diet at A SPE T Journals on July 16, 2023 jpet.aspetjournals.org D ow nloaded from 35 (CDAA) model (De Minicis et al., 2014).”
BackgroundPu, S., Liu, T., Gao, Y., Wu, Z.-Y., & Liu, S. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115013 · Cited by 13
Udoh, U. S., Sanabria, J. D., Rajan, P. K., Banerjee, M., Schade, M. S., Sanabria, J. A., Smith, G., Udoh, G., Sodhi, K., Pierre, S. V., et al. (2021) · Exon Publications eBooks · doi:10.36255/exonpublications.livercancer.2021.ch3 · Cited by 9
An oxidative stress paradox: time for a conceptual change?
Haas, J. T., & Staels, B. (2016) · Diabetologia · doi:10.1007/s00125-016-4117-y · Cited by 9
“Here, the authors challenged mice with a CDAA diet, which induces NASH pathology in the context of normal weight gain (not obesity) [12].”
BackgroundAbnormalities of intracellular organelles in metabolic dysfunction-associated steatotic disease
Kido, H., Mizukoshi, E., Yanagi, M., Li, S., Seike, T., Nakagawa, H., Yamashima, T., Shiraishi, Y., Ozaki, N., Harada, K., et al. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-025-02257-5 · Cited by 10
Serum resistin and the risk for hepatocellular carcinoma in diabetic patients
Abdalla, M. M. I. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i27.4271 · Cited by 8
Animal models for hepatocellular carcinoma arising from alcoholic and metabolic liver diseases
Liu, K., Chen, J., & McCaughan, G. W. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2019.39 · Cited by 9
“Combination diets such as CD-HFD and CDAA have been shown to significantly increase rates of tumour formation, although overall rates are still low: 25% after 12 months and 35% after 9 months, respectively([55,56]).”
BackgroundYadav, A. K., Sata, T. N., Verma, D., Sah, A. K., Mishra, A. K., Mrinalini, Hossain, M. M., Pant, K., & Venugopal, S. K. (2023) · iLiver · doi:10.1016/j.iliver.2023.01.002 · Cited by 9
Ali, F. E. M., Ibrahim, I. M., Althagafy, H. S., & Hassanein, E. H. M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112011 · Cited by 7
Zhang, D., Zheng, J., Qiu, G., Niu, T., Gong, Y., & Cui, S. (2022) · Human & Experimental Toxicology · doi:10.1177/09603271221135033 · Cited by 7
Eslami, Z., Mirghani, S. J., Moghanlou, A. E., Norouzi, A., Naseh, H., Joshaghani, H., Peres, W. A. F., Younesian, O., Hosseinzadeh, S., & Bideskan, J. A. (2021) · Hepatitis Monthly · doi:10.5812/hepatmon.117696 · Cited by 5
Chrysavgis, L., & Cholongitas, Ε. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21938-2.00020-5 · Cited by 3
Zhang, Y., Shen, L., Wang, B., & Wu, X. (2023) · PeerJ · doi:10.7717/peerj.15834 · Cited by 3
Lin, T., Tian, Z., Song, Z., Yang, F., Wang, C., & Ning, Z. (2025) · Guidelines and Standards of Chinese Medicine · doi:10.1097/gscm.0000000000000072 · Cited by 2
Dietary Rhythms and MASLD-Related Hepatocellular Carcinoma
Malakmahmoudi, N., Pisu, R., Laconi, E., & Marongiu, F. (2024) · Cancers · doi:10.3390/cancers16203481 · Cited by 3
Evaluation and impact of different biomarkers for early detection of hepatocellular carcinoma
Best, J., Sydor, S., Bechmann, L. P., & Canbay, A. E. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.56 · Cited by 3
“nonalcoholic fatty liver (NAFL) to NASH, but needs to be recognized as an individual predisposing HCC-risk factor since peripheral insulin resistance may promote hepatocarcinogenesis even in the absence of cirrhosis([4]).”
BackgroundInvestigating the therapeutic potential of low-level laser therapy in mitigating liver fibrosis
Mohamed, A. E., Mahmoud, A. M., Mohamed, W. R., & Mohamed, T. A. (2024) · Laser Innovations for Research and Applications. · doi:10.21608/lira.2024.357511 · Cited by 1
Vozza, A., Biagi, F., Chiara, R., Vizzutti, F., & Marra, F. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04456-1 · Cited by 1
“This concept is consistent with earlier MASH–HCC models showing that insulin resistance may promote hepatocarcinogenesis even in the absence of cirrhosis, in a model combining CDAA with low-dose CCl 4 injection [105].”
Rosmorduc, O., & Fartoux, L. (2014) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31173-2 · Cited by 3
“[20] De Minicis S, Agostinelli L, Rychlicki C, Sorice JP, Saccomanno S, Candelaresi C et al.”
BackgroundHepatocellular Carcinoma in Nonalcoholic Steatohepatitis
Koppe, S., & Arshad, H. M. S. (2017) · Digestive Disease Interventions · doi:10.1055/s-0037-1603572
WITHDRAWN: Rodent models of fatty liver diseases
Bertola, A. (2018) · Liver Research · doi:10.1016/j.livres.2018.02.005
RetractedBenedetti, A., Campanati, A., Martina, E., Simonetti, O., Bendia, E., Sario, A. D., Maroni, L., Marzioni, M., Pierantonelli, I., Sassaroli, P., et al. (2020) · Springer eBooks · doi:10.1007/978-3-030-33832-9_16
Self-citationBellentani, S., & Rosso, N. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.731388417.793537618
Monoacylglycerol Lipase, a new anti-inflammatory and anti-fibrogenic target in the liver
Chokr, D. (2018) · theses.fr (ABES) · doi:10.70675/6aac5cc4z3085z4939zb6c9ze439b795571f
Guilcher, C. L. (2018) · theses.fr (ABES) · doi:10.70675/31755573zc52bz4020zb736za39dcd3e9230
Role of RIPK1 in the survival and death of hepatocytes : its involvement in murine hepatitis models
Farooq, M. (2019) · theses.fr (ABES) · doi:10.70675/5fe7950dz1147z4d64z9b9bz87bfd1d3ae35
Outcome of liver transplantation for hepatocellular carcinoma within and beyond Milan criteria
Mourad, M. G. (2019) · theses.fr (ABES) · doi:10.70675/f5028a6dz55e9z4066zb918z9ffcc4b218b4
Influence du sexe dans la susceptibilité aux hépatopathies métaboliques
Smati, S. (2019) · theses.fr (ABES) · doi:10.70675/01997f55za990z41e6z96baz8221de2a6281
Rôle de REG3A dans la maladie métabolique du foie d'origine nutritionnelle
Nguyen, T.-S. (2024) · theses.fr (ABES) · doi:10.70675/2c0ffdcfz96ccz43b0z8e03zb358f83e528d
Metadata
- Authors
- De Minicis, S., Agostinelli, L., Rychlicki, C., Sorice, G. P., Saccomanno, S., Candelaresi, C., Giaccari, A., Trozzi, L., Pierantonelli, I., Mingarelli, E., Marzioni, M., Muscogiuri, G., Gaggini, M., Benedetti, A., Gastaldelli, A., Guido, M., & Svegliati-Baroni, G.
- Affiliations
- Marche Polytechnic University (IT)
- Università Cattolica del Sacro Cuore (IT)
- Istituto di Fisiologia Clinica (IT)
- University of Padua (IT)
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-05-22
- Volume
- 9
- Issue
- 5
- Pages
- e97136
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4031080
- OpenAlex
- W2086542332
- Cited by
- 97
- References
- 53
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 6 · 2023: 8 · 2022: 7 · 2021: 10 · 2020: 16 · 2019: 12 · 2018: 12 · 2017: 7 · 2016: 6 · 2015: 5 · 2014: 1
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by)
- Funders
- European Commission (241762)
- Ministero della Salute (GR-2010, GR-2010-2306996)
- Ministero dell’Istruzione, dell’Università e della Ricerca (2007–2013, PRIN 2009, FIRB2010, 2009X84L84_003)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- hepatocellular carcinoma, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, peripheral insulin resistance, choline-deficient L-amino acid-defined diet, carbon tetrachloride, liver fibrosis, hepatic steatosis, insulin-like growth factor II, osteopontin, Akt phosphorylation, c-Myc, glypican-3, hepatocarcinogenesis, mouse model
- MeSH terms
- Age Factors, Animals, Choline Deficiency, Disease Models, Animal, Food, Formulated, Carcinoma, Hepatocellular, Insulin Resistance, Insulin-Like Growth Factor II, Liver Neoplasms, Proto-Oncogene Proteins c-myc, Mice, Osteopontin, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.